DANAHER CORP /DE/

DHR 10-Q · Q1 2026
API behind this page

DHR Q1 2026 request

Playground key active
Request URL /api/financials?ticker=DHR&year=2026&quarter=1
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q1 2026 Q1 2025 YoY
Revenue 5,951 5,741 +3.7%
Show Product Lines breakouts
Nonrecurring revenue 920 925 -0.5%
Nonrecurring revenue · Biotechnology 155 155 0.0%
Nonrecurring revenue · Diagnostics 231 226 +2.2%
Nonrecurring revenue · Life Sciences 534 544 -1.8%
Recurring revenue 5,031 4,816 +4.5%
Recurring revenue · Biotechnology 1,642 1,457 +12.7%
Recurring revenue · Diagnostics 2,186 2,223 -1.7%
Recurring revenue · Life Sciences 1,203 1,136 +5.9%
Show Business Segments breakouts
Biotechnology · High-growth markets 490 439 +11.6%
Biotechnology · North America 524 543 -3.5%
Biotechnology · Operating Segments 1,797 1,612 +11.5%
Biotechnology · Other developed markets 57 64 -10.9%
Biotechnology · Western Europe 726 566 +28.3%
Diagnostics · High-growth markets 635 640 -0.8%
Diagnostics · North America 1,265 1,318 -4.0%
Diagnostics · Operating Segments 2,417 2,449 -1.3%
Diagnostics · Other developed markets 86 91 -5.5%
Diagnostics · Western Europe 431 400 +7.8%
Life Sciences · High-growth markets 499 458 +9.0%
Life Sciences · North America 689 721 -4.4%
Life Sciences · Operating Segments 1,737 1,680 +3.4%
Life Sciences · Other developed markets 141 123 +14.6%
Life Sciences · Western Europe 408 378 +7.9%
Show Geography breakouts
High-growth markets 1,624 1,537 +5.7%
North America 2,478 2,582 -4.0%
Other developed markets 284 278 +2.2%
Western Europe 1,565 1,344 +16.4%
Show Consolidation Items breakouts
Operating Segments 5,951 5,741 +3.7%
Cost of Revenue -2,360 -2,230 -5.8%
Gross Profit 3,591 3,511 +2.3%
Selling, General & Administrative -1,860 -1,858 -0.1%
Research & Development -387 -379 -2.1%
Operating Income 1,344 1,274 +5.5%
Show Business Segments breakouts
Biotechnology · Operating Segments 534 441 +21.1%
Diagnostics · Operating Segments 674 718 -6.1%
Life Sciences · Operating Segments 225 201 +11.9%
Show Consolidation Items breakouts
Corporate Non Segment -89 -86 -3.5%
Operating Segments 1,433 1,360 +5.4%
Other Non-Operating Income (Expense) -73 -79 +7.6%
Interest Expense -63 -72 +12.5%
Interest Income 27 6 +350.0%
Income Before Taxes 1,235 1,129 +9.4%
Income Tax Expense (Benefit) -206 -175 -17.7%
Net Income 1,029 954 +7.9%
Show Equity Components breakouts
Retained Earnings 1,029 954 +7.9%
EPS (Basic) 1.45 1.33 +9.0%
EPS (Diluted) 1.45 1.32 +9.8%
Wtd Avg Shares (Basic) 707.9 716.3 -1.2%
Wtd Avg Shares (Diluted) 711.2 720.8 -1.3%
Comprehensive Income 643 2,560 -74.9%
Gain Loss On Investments -77 -90 +14.4%

Balance Sheet

Balance Sheet
Metric Q1 2026 Q1 2025 YoY
Current Assets
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 5,701 1,993 +186.1%
Accounts Receivable 3,819 3,506 +8.9%
Inventory Finished Goods Net Of Reserves 1,360 1,272 +6.9%
Inventory Work In Process Net Of Reserves 504 517 -2.5%
Inventory Raw Materials Net Of Reserves 744 743 +0.1%
Inventory 2,608 2,532 +3.0%
Prepaid Expenses & Other Current Assets 1,807 1,494 +21.0%
Total Current Assets 13,935 9,525 +46.3%
Non-Current Assets
Property, Plant & Equipment 5,468 5,110 +7.0%
Other Non-Current Assets 4,210 3,939 +6.9%
Goodwill 42,765 41,657 +2.7%
Show Business Segments breakouts
Biotechnology · Operating Segments 22,999 22,315 +3.1%
Diagnostics · Operating Segments 6,961 — —
Life Sciences · Operating Segments 12,805 — —
Total Assets 83,544 79,116 +5.6%
Show Business Segments breakouts
Biotechnology · Operating Segments 36,697 36,121 +1.6%
Diagnostics · Operating Segments 14,657 — —
Life Sciences · Operating Segments 22,873 — —
Show Consolidation Items breakouts
Corporate Non Segment 9,317 5,308 +75.5%
Operating Lease Right-of-Use Assets 1.2 1.1 +9.1%
Other Assets
Intangible Assets Net Excluding Goodwill 17,166 18,885 -9.1%
Current Liabilities
Debt Current 923 501 +84.2%
Accounts Payable Trade Current 1,790 1,722 +3.9%
Accrued Liabilities 4,747 4,422 +7.3%
Total Current Liabilities 7,460 6,645 +12.3%
Non-Current Liabilities
Other Non-Current Liabilities 5,566 5,638 -1.3%
Long-Term Debt 17,561 15,976 +9.9%
Show Debt Instrument breakouts
Euro-denominated commercial paper 2.8 — —
Long-Term Debt 18,484 16,477 +12.2%
Show Debt Instrument breakouts
0.3% senior notes due 2027 · Senior Notes 192 205 -6.3%
0.45% senior notes due 2028 · Senior Notes 1,437 1,349 +6.5%
0.4773% 2027 CHF Bonds · Bonds 312 — —
0.65% senior notes due 2032 · Senior Notes 331 354 -6.5%
0.75% senior notes due 2031 · Senior Notes 2,009 1,887 +6.5%
0.8875% 2029 CHF Bonds · Bonds 405 — —
1.125% senior bonds due 2028 · Bonds 264 240 +10.0%
1.2% senior notes due 2027 · Senior Notes 690 648 +6.5%
1.265% 2033 CHF Bonds · Bonds 405 — —
1.35% senior notes due 2039 · Senior Notes 1,427 1,340 +6.5%
1.6249% 2037 CHF Bonds · Bonds 280 — —
1.8% senior notes due 2049 · Senior Notes 857 804 +6.6%
1.94% 2045 CHF Bonds · Bonds 155 — —
2.1% senior notes due 2026 · Senior Notes 921 865 +6.5%
2.5% senior notes due 2030 · Senior Notes 921 866 +6.4%
2.6% senior notes due 2029 · Senior Notes 798 797 +0.1%
2.6% senior notes due 2050 · Senior Notes 983 982 +0.1%
2.8% senior unsecured notes due 2051 · Senior Notes 987 985 +0.2%
3.25% senior notes due 2039 · Senior Notes 892 892 0.0%
3.4% senior notes due 2049 · Senior Notes 891 890 +0.1%
4.375% senior notes due 2045 · Senior Notes 500 499 +0.2%
Euro-denominated commercial paper · Commercial Paper 2.5 931 -99.7%
Other 2 14 -85.7%
Stockholders' Equity
Common Stock 9 9 0.0%
Additional Paid In Capital Common Stock 17,303 16,845 +2.7%
Treasury Stock Common Value -11,407 -9,306 -22.6%
Retained Earnings 47,637 44,913 +6.1%
Accumulated Other Comprehensive Income -593 -1,612 +63.2%
Total Stockholders' Equity 52,949 50,849 +4.1%
Minority Interest 8 8 0.0%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest 52,957 50,857 +4.1%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment -184 -299 +38.5%
Accumulated Gain Loss Net Cash Flow Hedge Parent 224 142 +57.7%
Accumulated Other Comprehensive Income -593 -1,612 +63.2%
Accumulated Translation Adjustment -633 -1,455 +56.5%
Additional Paid In Capital 17,303 16,845 +2.7%
Common Stock 9 9 0.0%
Noncontrolling Interest 8 8 0.0%
Retained Earnings 47,637 44,913 +6.1%
Treasury Stock Common -11,407 -9,306 -22.6%
Total Liabilities & Equity 83,544 79,116 +5.6%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q1 2026 YTD Q1 2025 YoY
Operating Activities
Depreciation 193 181 +6.6%
Show Business Segments breakouts
Biotechnology · Operating Segments 40 34 +17.6%
Diagnostics · Operating Segments 102 100 +2.0%
Life Sciences · Operating Segments 48 45 +6.7%
Show Consolidation Items breakouts
Corporate Non Segment 3 2 +50.0%
Operating Segments 190 179 +6.1%
Amortization Of Intangible Assets 434 410 +5.9%
Show Business Segments breakouts
Biotechnology · Operating Segments 234 213 +9.9%
Diagnostics · Operating Segments 48 48 0.0%
Life Sciences · Operating Segments 152 149 +2.0%
Show Consolidation Items breakouts
Operating Segments 434 410 +5.9%
Stock-Based Compensation 58 61 -4.9%
Investment Gains Losses And Pretax Gain On Sale Of Product Line 77 81 -4.9%
Change in Accounts Receivable 66 89 -25.8%
Change in Inventory -132 -166 +20.5%
Change in Accounts Payable -41 -61 +32.8%
Change in Prepaid & Other Assets -40 -32 -25.0%
Increase Decrease In Other Accounts Payable And Accrued Liabilities -322 -233 -38.2%
Net Cash from Operations 1,322 1,299 +1.8%
Investing Activities
Capital Expenditures -237 -245 +3.3%
Payments To Acquire Investments -20 -18 -11.1%
Other Investing Activities 8 1 +700.0%
Net Cash from Investing -249 -242 -2.9%
Financing Activities
Payments For Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options -9 -5 -80.0%
Payments Of Dividends -226 -194 -16.5%
Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less 1,743 -3 +58200.0%
Repayments Of Debt Maturing In More Than Three Months -1,434 — —
Proceeds From Payments For Other Financing Activities -28 21 -233.3%
Net Cash from Financing 46 -1,255 +103.7%
Supplemental
Interest Paid 28 63 -55.6%
Income Taxes Paid 191 201 -5.0%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents -33 113 -129.2%
Net Change in Cash 1,086 -85 +1377.6%

Values in millions USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key